| Author | Bias | Study/ type | Quality | Popln- no. | Outcomes | Effect size | CI or p | Follow up | Scoring method | Adverse effects |
|--|---|--|---------|---|---|--|------------------------------------|--|---|--|
| Author | Dias | Study/ type | rating | in each arm | measured | Effect size | value | Tollow up | Scoring method | Adverse effects |
| Kumara n et al India 2006 | Selec tive recrui tment | methods none on interests | 2+ | Adults- 15, 16, 18- 4 did not complete | Betamethasone, vs calcipotriol, vs combination. Not placebo controlled. Result favoured combination. Onset 5-10 wk | 2, 1, 4 all out of 15, for >50% repig | t test, & chi square test | 12 weeks treatment plus further 8 weeks | Only 1 selected lesion scored- photo & trace | Skin atrophy noted |
| Coskun et al Turkey 2005 | Small numb ers | 0 | 2+ | Adults- 10, right vs left compare | Clobetasol vs pimecrolimus. Not placebo controlled. Effects equal, best for trunk or extremities, started in 3 wk | 50-100% repig found in 7& 8 /10 | SPSS | 8 weeks treatment only | Independent observers of photos of 2 selected lesions | No skin atrophy. Some burning |
| Lepe et al Mexico 2003 | Poor effect | side was randomised. No 'financial' interest declared | 1+ | Children (<18y) - 20, right vs left compare | Tacrolimus vs clobetasol. Not placebo controlled. Effects 41% vs 49%. Onset 3 wks for both Rx. | 'Deg ree' of repig was 41% vs 49% | Paired t test, K test | 8 weeks treatment | Independent observers of photos of 2 selected lesions | Skin atrophy in 5 with steroid, burning in 2 with tacrolimus |
| Wester hof et al Holland 1999 | Good | Left vs right comparison, side randomised – not said how. No comment on interests but Glaxo author | 1++ | Adults, 135 at start, 96 evaluated. Exclude face & hands | Fluticasone (FP) alone vs FP + UVA vs UVA alone. Not placebo controlled. FP+ UVA x3 better than FP or UVA alone. | Mean repig at 9 mo 7.7% vs 24% vs 9.0% intent to Rx | Wilco xon match ed pairs | 9 months treatment | One observer assess ed photos of 2 selected lesions | No side effects reported except atrophy in 2 patients with UVA |
| Khalid et al Pakistan 1995 | Poor on detail | Randomised – not said how. No comment on interests | 1+ | Children <12, 50 at start. 45 evaluated. Exclude segmental and mucosal | Clobetasol top x2/day vs 8- methoxy -psoralen ointment plus sun exposure x3/week (PUVAsol). Not placebo controlled. | Repig >50% seen 15/22 clob vs 4/23 PUV- Asol. | None | 6 months treatment | Not stated – implies all vitiligo areas. Poor resp hands feet | 2 patients stopped PUVAsol due to blistering. 6 developed atrophy with steroid |
| Clayton London 1977 | Good consi derin g | comparison, | 1+ | Not stated. 25 subjects | Clobetasol cream vs placebo cream for 8 weeks. | Repig 15- 25% in 10/23, >75% in 2/23 steroid, >75% 2/23 base | Sign test | 4 months treatment | Not stated- implies all areas | All users of steroid got dermal atrophy |
| Kandil Kuwait 1974 | Meth od questi oned- Rx to both sides | stated how. | 1+ | Not stated 19 subjects, 17 comp leted | Betamethasone lotion vs base | Repig in 25-90% in 3, 90-100% in 6 (of 19) for steroid Rx side vs 0 for placebo | none | 4 months treatment | Not stated- implies all areas | Hyper-trichosis in 2, acne in 3 both with steroid |